“So that's the cadence that you should expect. And as Geoff mentioned in his opening comments, we have next-generation products that we discussed at ADA last year that we continue to make progress on and aggressively moving to get next-generation tethered pumps and patch pumps out to the market.”

In context

“ss. So we're really, really good at it. And the feedback has been excellent. The procedure efficiency on PulseSelect has been -- we're getting these cases done in like a half an hour, and the acceptance on Aurora has been exceptional too. So as I said I think it's the same story for both of those technologies, where you push growth now but into next year will the full impact of these innovations. Geoff Martha: Que, you want to comment on diabetes? Que Dallara: Yeah, look, we continue to push the pipeline in diabetes. Starting with Simplera approved with CE Mark last September, followed by Simplera Sync recently approved that we announced at JPMorgan. And we completed our clinical trials for 780G with Simplera Sync in the US, which we expect to make in this first half of the calendar year. So that's the cadence that you should expect. And as Geoff mentioned in his opening comments, we have next-generation products that we discussed at ADA last year that we continue to make progress on and aggressively moving to get next-generation tethered pumps and patch pumps out to the market. Ryan Weispfenning: Okay. Thank you. Geoff Martha: Thanks, Que. Thanks, Sean. Ryan Weispfenning: Thanks, Matt. I apologize to the analysts that we weren't able to get to. We have time now for one more, Brad. Brad Welnick: The final question comes from Anthony Petrone at Mizuho Securities. Anthony, please go ahead. Anthony Petrone: Thanks. Can you hear me okay? Geoff Martha: Yeah. Anthony, we can. Anthony Petrone: Okay, great. Geoff Martha: Yeah, Anthony, we can hear you. Anthony Petrone: Just on -- one condolences on the passing of Tom to the team and his family. And maybe one just going to Structural Heart, maybe just to set up on SMART Study, quick two-part question. One was that ahead of schedule, was it expected to be at TCT instead of ACC. So as the late-breaker getting approved the s”